South East Asia Swine Vaccines Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

South East Asia Swine Vaccines Market Segmentation, By Pathogen (Virus and Bacteria), Indication (Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCV/PCVD), Swine Fever, Foot-And-Mouth Disease (FMD), Porcine Pneumonia, Porcine Parovirus, Glaesserella Parasuis, and Others), Technology (Inactivated Vaccines. Recombinant Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, and Others), Product (Ingelvac, Porcilis, Improvac, Prevacent, Enterisol, Cirbloc M Hyo, Bioaftogen, Enradin, Yuan Ke Xin, Circovac, Hyogen, Salmoporc, Ecoporc Shiga, Parvoruvax, Enteroporc Coli Ac, Navet-Asfvac & Avac Asf Live, Coglapix, Progressis, Ruilan, Vepured, Suigen, Shield, Ruifute-Wang, Refute, Ruiyuanshu, Clear The False Spirit, and Others), Demographic (Piglet and Adult), Route of administration (Intramuscular, Subcutaneous, Others), Distribution Channel (Hospitals and Clinics, Retail Pharmacies, E-commerce Platforms, and Others) - Industry Trends and Forecast to 2032

 Swine Vaccines Market Size

• The South East Asia Swine Vaccines Market size was valued at USD 1.06 billion in 2024 and is expected to reach USD 1.73 billion by 2032, at a CAGR of 6.3% during the forecast period
• This growth is driven by factors such as the rising incidence of swine diseases

Swine Vaccines Market Analysis

• Swine vaccines play a crucial role in the South East Asia Swine Vaccines Market, serving as vital tools for preventing diseases in swine populations. These vaccines help improve livestock health and productivity, supporting the region's agricultural industry and ensuring food security. They are particularly important for controlling outbreaks and minimizing economic losses
• The demand for these microscopes is significantly driven by rising incidence of swine diseases, higher pork consumption across southeast Asian countries
• China is expected to dominate the swine vaccines market with a share of 45.24%,  due to its expanding livestock industry and increasing adoption of advanced veterinary healthcare practices
• China is expected to be the fastest growing region in the swine vaccines market during the forecast period due to increasing demand for effective vaccination solutions and growing awareness of swine health management
• Virus segment is expected to dominate the market with a market share of 66.58% to its high prevalence and the growing demand for effective vaccination solutions to prevent viral diseases in swine populations

Report Scope and Swine Vaccines Market Segmentation      

Swine Vaccines Market Trends

“Advancements in Vaccination Technologies & Delivery Methods”

• A prominent trend in the evolution of the South East Asia swine vaccines market is the increasing development of innovative vaccine formulations and delivery methods
• These advancements improve immunization efficacy by providing broader protection and more efficient administration, thereby enhancing overall herd health management in the region

• For instance, modern vaccine development and delivery techniques in the South East Asia swine vaccines market offer enhanced immune response and broader herd immunity, facilitating better disease control and prevention

• These advancements are transforming swine health management, improving overall livestock productivity, and driving the demand for next-generation vaccines with improved efficacy and innovative administration methods

Swine Vaccines Market Dynamics

Driver

“Rising Incidence of Swine Diseases”

• The rising incidence of swine diseases, particularly African Swine Fever (ASF), Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), and Porcine Epidemic Diarrhea Virus (PEDV), has significantly impacted the pig industry across Southeast Asia
• As the growing frequency and severity of swine disease outbreaks are driving urgent demand for effective vaccines, positioning the Southeast Asia swine vaccines market for substantial growth
• As more swine populations are vaccinated to prevent infectious diseases, the demand for effective vaccines increases, ensuring better herd health and reducing the risks associated with disease outbreaks in the South East Asia region

For instance,

• In July 2020, according to the article published by NCBI, the rising incidence of swine diseases such as African swine fever virus (ASFV), PRRSV, PEDV, and FMDV continues to severely impact Asia’s pig industry, which holds over 50% of the global pig population. Factors like diverse production systems, animal movement, and globalization fuel rapid disease spread, driving strong demand for effective swine vaccines in the South East Asia market

• As a result, the growing frequency and severity of swine disease outbreaks are driving urgent demand for effective vaccines, positioning the Southeast Asia swine vaccines market for substantial growth

Opportunity

“Innovations in Vaccine Technologies”

• Traditional vaccines have been complemented by novel approaches such as DNA and mRNA vaccines, which offer quicker development and adaptability to emerging pathogens. These next-generation vaccines promise enhanced safety and efficacy, with reduced production times and improved stability
• In addition, vector-based vaccines, which use harmless viruses to deliver antigens, are being explored for their ability to induce stronger immune responses. Adjuvants have also evolved, enhancing vaccine effectiveness by boosting the immune system's response
• Moreover, oral and needle-free vaccine delivery systems improve ease of administration and animal welfare. These advancements aim to control endemic diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS) and improve overall herd health, thereby increasing productivity and profitability in the swine industry

For instance,

• In March 2025, as per an article published by MDPI paper highlights key innovations in African Swine Fever control, including development of live attenuated vaccines like ASFV-G-ΔI177L, rapid diagnostic tools such as RPA assays, and modeling herd immunity thresholds. These advances aim to improve prevention and containment strategies, especially for small-scale swine farms in Southeast Asia

• The region is witnessing a surge in vaccine development, particularly against PRRS, classical swine fever, and other endemic diseases. Government initiatives promoting biosecurity, along with farmer education on vaccination benefits, are driving market expansion

Restraint/Challenge

“Complexity Of Vaccination Protocols And Factors”

• A significant restraint in the Southeast Asia swine vaccine market is the complexity of vaccination protocols and the various factors that negatively impact vaccine efficacy
• These factors include stress, microbiome variations, and maternal-derived antibodies (MDAs), which interfere with immune responses. While some factors are well understood, many remain inadequately researched, creating uncertainty regarding vaccine effectiveness.
• This lack of comprehensive knowledge leads to skepticism among animal owners and veterinarians, undermining confidence in vaccines as a viable alternative to antibiotics

For instance,

• In August 2024, as per the article published by MDPI, the complexity of vaccination protocols, including the need for stringent biosecurity measures and comprehensive surveillance, impacts the efficacy of vaccines in Southeast Asia. As highlighted by WOAH’s concerns and the emergence of field vaccine-related viruses, improper vaccine application can result in significant challenges. The lack of standardized protocols and independent bodies for vaccine evaluation hinders effective disease control, acting as a restraint for the Southeast Asia swine vaccines market

• The complexity of vaccination protocols, compounded by factors such as stress, microbiome variations, and maternal-derived antibodies (MDAs), presents significant challenges to the effective application of vaccines in Southeast Asia’s swine industry

Swine Vaccines Market Scope

The market is segmented on the basis of pathogen, indication, technology, product, demographic, route of administration, and distribution channel.

In 2025, the Virus is projected to dominate the market with a largest share in application segment

The virus segment is expected to dominate the swine vaccines market with the largest share of 66.58%  in 2025 due to the high prevalence of viral diseases among swine populations and the growing demand for targeted vaccination solutions. As a critical measure for disease prevention, advancements in vaccine technology and immunization strategies are expected to improve efficacy and boost market growth. Rising awareness of animal health management and government programs further contribute to its market dominance.

The Porcine Reproductive and Respiratory Syndrome (PRRS)  is expected to account for the largest share during the forecast period in technology segment

In 2025, the Porcine Reproductive and Respiratory Syndrome (PRRS) segment is expected to dominate the market with the largest market share of 24.29% due to its high prevalence and demand for effective vaccination solutions. As a major concern for swine health, advancements in vaccine development and immunization protocols are expected to enhance disease control, driving market growth. Increasing awareness of biosecurity measures and government initiatives further contribute to its market dominance.

Swine Vaccines Market Regional Analysis

“China Holds the Largest Share in the Swine Vaccines Market”

• China dominates the swine vaccines market with market share 45.24%, driven by expanding livestock populations, increasing investment in animal health infrastructure, and the presence of key regional market players
• The China holds a significant share due to rising awareness of swine disease management, government initiatives to improve livestock health, and the increasing prevalence of viral and bacterial infections among swine populations
• The availability of supportive policies for animal health and rising investments in research & development by pharmaceutical companies further strengthen the market.
• In addition, the growing demand for automated vaccination systems and improved biosecurity measures, along with rising industrial pig farming, are fueling market growth across the region

“China is Projected to Register the Highest CAGR in the Swine Vaccines Market”

• China is expected to witness substantial growth in the Swine Vaccines market, driven by increasing adoption of animal health management practices, expanding livestock industries, and rising awareness about disease prevention
• Countries such as Thailand, Vietnam, and Indonesia are emerging as key markets due to their growing pig populations, rising incidences of swine diseases, and government initiatives to improve animal health standards
• Vietnam and Thailand, with their expanding pig farming sectors and increasing investments in veterinary healthcare, are becoming important markets for swine vaccines. The focus on biosecurity and disease control measures continues to promote market expansion
• In addition, the rising demand for safe and effective vaccination programs, along with the presence of global pharmaceutical companies and improved veterinary infrastructure, further drive market growth across South East Asia

Swine Vaccines Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Boehringer Ingelheim International GmbH (Germany)
• Merck & Co., Inc. (U.S.)
• Zoetis Inc. (U.S.)
• Ceva (France)
• Pulike Biological Engineering Co., Ltd. (China)
• Elanco Animal Health Incorporated (U.S.)
• Biogénesis Bagó S.A. (Argentina)
• HIPRA, S.A. (Spain)
• Jinyu Bio-Technology Co., Ltd. (China)
• Shanghai Shen Lian Biomedical Corporation (China)
• China Animal Husbandry Industry Co., Ltd. (China)
• ESCO ASTER PTE. LTD. (Singapore)
• Shanghai Haili Biotechnology Co., Ltd. (China)
• AVAC Vietnam Joint Stock Company (Vietnam)
• Bimeda Biologicals Ltd. (Ireland)
• Harbin Harvac Biotechnology Co., Ltd. (China)
• Virbac S.A. (France)

Latest Developments in South East Asia Swine Vaccines Market

• In November 2024, Boehringer Ingelheim’s vaccine for Leptospirosis in dogs is designed to protect against the bacteria Leptospira that cause the disease. This vaccine provides immunity against the most common strains of Leptospira, which can lead to severe liver and kidney damage, and can even be fatal. By vaccinating dogs, pet owners can significantly reduce the risk of infection from environmental exposure to contaminated water or soil. The vaccine promotes long-lasting protection, contributing to overall dog health and preventing the spread of the disease to other animals or humans, ensuring safer environments for pets and their families
• In November 2024, Boehringer Ingelheim launches Vetmedin Oral Solution for dogs with congestive heart failure (CHF). This new formulation offers an easy-to-administer solution to improve heart function in dogs suffering from CHF, a condition often caused by mitral valve disease or dilated cardiomyopathy. Vetmedin works by enhancing the heart’s ability to pump blood and reducing symptoms like coughing, fatigue, and difficulty breathing. This solution provides a convenient treatment option, helping to improve the quality of life and longevity of affected dogs, making heart failure management more effective and accessible for pet owners and veterinarians alike
• In September, Merck Animal Health has received EU marketing authorization for PORCILIS PCV M Hyo ID, an intradermal, needle-free swine vaccine protecting against PCV2 and M. hyo. Delivered via IDAL technology, it offers efficient, low-volume administration with enhanced animal welfare. Launching in Q1 2025, the vaccine supports sustainability, co-administration with other vaccines, and improved disease protection for piglets
• In July 2020, Zoetis has acquired Fish Vet Group from Benchmark Holdings to enhance its Pharmaq aquaculture business. The acquisition expands Pharmaq’s diagnostic and environmental testing capabilities across key markets, including the UK, Norway, Ireland, and Chile. Fish Vet Group’s services support sustainable aquaculture by aiding disease management, environmental compliance, and site assessments, strengthening Zoetis’ position in global fish health solutions 

SKU-74038